Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.

Martín V, Vidal J, Malkin SJP, Hallén N, Hunt B

Advances in therapy29 Aug 2020Cited by 12 (Europe PMC)

PMID32862365DOI10.1007/s12325-020-01464-1PepBankPUB-32862365

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study17

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone17

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 0.5 mg increased projected discounted life expectancy versus dulaglutide.
In plain wordsIn a computer model of diabetes, semaglutide 0.5 mg increased projected lifespan compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseProjected life expectancy, lower dose versus dulaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Life expectancy gain
0.02 years
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236501
02Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 1 mg increased projected discounted life expectancy versus dulaglutide.
In plain wordsIn a computer model of diabetes, semaglutide 1 mg increased projected lifespan compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseProjected life expectancy, higher dose versus dulaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Life expectancy gain
0.11 years
semaglutide 1 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236502
03Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 0.5 mg increased projected quality-adjusted life expectancy versus dulaglutide.
In plain wordsIn a computer model of diabetes, semaglutide 0.5 mg increased projected life adjusted for health quality compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseProjected quality-adjusted life expectancy, lower dose versus dulaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Quality-adjusted life expectancy gain
0.03 QALYs
semaglutide 0.5 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236503
04Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 1 mg increased projected quality-adjusted life expectancy versus dulaglutide.
In plain wordsIn a computer model of diabetes, semaglutide 1 mg increased projected life adjusted for health quality compared with dulaglutide.
Peptide
Semaglutide
Outcome
IncreaseProjected quality-adjusted life expectancy, higher dose versus dulaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Quality-adjusted life expectancy gain
0.11 QALYs
semaglutide 1 mg versus dulaglutide 1.5 mg
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236504
05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a diabetes model, dulaglutide had lower projected discounted life expectancy than semaglutide 0.5 mg.
In plain wordsIn a computer model of diabetes, dulaglutide had lower projected lifespan than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseProjected life expectancy versus lower-dose semaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3286236505
06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a diabetes model, dulaglutide had lower projected discounted life expectancy than semaglutide 1 mg.
In plain wordsIn a computer model of diabetes, dulaglutide had lower projected lifespan than semaglutide 1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseProjected life expectancy versus higher-dose semaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3286236506
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a diabetes model, dulaglutide had lower projected quality-adjusted life expectancy than semaglutide 0.5 mg.
In plain wordsIn a computer model of diabetes, dulaglutide had lower projected life adjusted for health quality than semaglutide 0.5 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseProjected quality-adjusted life expectancy versus lower-dose semaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3286236507
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a diabetes model, dulaglutide had lower projected quality-adjusted life expectancy than semaglutide 1 mg.
In plain wordsIn a computer model of diabetes, dulaglutide had lower projected life adjusted for health quality than semaglutide 1 mg.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseProjected quality-adjusted life expectancy versus higher-dose semaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Projections of long-term clinical outcomes indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.02 and 0.11 years, respectively, and discounted quality-adjusted life expectancy of 0.03 and 0.11 quality-adjusted life years (QALYs)…
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3286236508
09Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 0.5 mg increased projected discounted life expectancy versus sitagliptin.
In plain wordsIn a computer model of diabetes, semaglutide 0.5 mg increased projected lifespan compared with sitagliptin.
Peptide
Semaglutide
Outcome
IncreaseProjected life expectancy, lower dose versus sitagliptin
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Life expectancy gain
0.17 years
semaglutide 0.5 mg versus sitagliptin
Source sentences
Summary
Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236509
10Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 1 mg increased projected discounted life expectancy versus sitagliptin.
In plain wordsIn a computer model of diabetes, semaglutide 1 mg increased projected lifespan compared with sitagliptin.
Peptide
Semaglutide
Outcome
IncreaseProjected life expectancy, higher dose versus sitagliptin
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Life expectancy gain
0.24 years
semaglutide 1 mg versus sitagliptin
Source sentences
Summary
Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236510
11Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 0.5 mg increased projected quality-adjusted life expectancy versus sitagliptin.
In plain wordsIn a computer model of diabetes, semaglutide 0.5 mg increased projected life adjusted for health quality compared with sitagliptin.
Peptide
Semaglutide
Outcome
IncreaseProjected quality-adjusted life expectancy, lower dose versus sitagliptin
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Quality-adjusted life expectancy gain
0.16 QALYs
semaglutide 0.5 mg versus sitagliptin
Source sentences
Summary
Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236511
12Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide 1 mg increased projected quality-adjusted life expectancy versus sitagliptin.
In plain wordsIn a computer model of diabetes, semaglutide 1 mg increased projected life adjusted for health quality compared with sitagliptin.
Peptide
Semaglutide
Outcome
IncreaseProjected quality-adjusted life expectancy, higher dose versus sitagliptin
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Sitagliptin
Outcome group
Cost-effectiveness · Whole body
Measurements
Quality-adjusted life expectancy gain
0.23 QALYs
semaglutide 1 mg versus sitagliptin
Source sentences
Summary
Compared with sitagliptin, once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.17 and 0.24 years, respectively and discounted quality-adjusted life expectancy of 0.16 and 0.23 QALYs.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236512
13Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide was associated with reduced cumulative incidence of diabetes-related complications.
In plain wordsIn a computer model of diabetes, semaglutide was associated with fewer projected diabetes complications.
Peptide
Semaglutide
Outcome
DecreaseProjected complication incidence
Study
n: not reported in source
IQVIA CORE Diabetes Model
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The increased duration and quality of life with once-weekly semaglutide 0.5 mg and 1 mg resulted from a reduced cumulative incidence and delayed time to onset of diabetes-related complications.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236513
14Computer modelNot a test of Semaglutide aloneIn silicoOther
In a diabetes model, semaglutide was associated with delayed onset of diabetes-related complications.
In plain wordsIn a computer model of diabetes, semaglutide was associated with later projected diabetes complications.
Peptide
Semaglutide
Outcome
IncreaseProjected complication onset
Study
n: not reported in source
IQVIA CORE Diabetes Model
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The increased duration and quality of life with once-weekly semaglutide 0.5 mg and 1 mg resulted from a reduced cumulative incidence and delayed time to onset of diabetes-related complications.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236514
15Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Spanish diabetes model, both semaglutide doses were cost-saving versus dulaglutide.
In plain wordsIn a Spanish computer model of diabetes, both semaglutide doses cost less than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseProjected costs versus dulaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Dulaglutide 1.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236515
16Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Spanish diabetes model, both semaglutide doses were cost-saving versus sitagliptin.
In plain wordsIn a Spanish computer model of diabetes, both semaglutide doses cost less than sitagliptin.
Peptide
Semaglutide
Outcome
DecreaseProjected costs versus sitagliptin
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Sitagliptin 100 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3286236516
17Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Spanish diabetes model, dulaglutide had higher projected costs than both semaglutide doses.
In plain wordsIn a Spanish computer model of diabetes, dulaglutide cost more than both semaglutide doses.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseProjected costs versus semaglutide
Study
n: not reported in source
IQVIA CORE Diabetes Model
Comparator
Semaglutide 0.5 or 1 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Avoided complications resulted in once-weekly semaglutide 0.5 mg and 1 mg being cost-saving versus dulaglutide 1.5 mg and versus sitagliptin 100 mg from a healthcare payer perspective.
2 context sentences(design, population, supporting numbers)
Summary · context
Cost and clinical outcomes were projected over patient lifetimes using the IQVIA CORE Diabetes Model.
Summary · context
Baseline cohort characteristics and treatment effects on initiation of semaglutide 0.5 mg and 1 mg, dulaglutide 1.5 mg and sitagliptin 100 mg were based on the once-weekly semaglutide clinical trial program (SUSTAIN 7 and 2).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3286236517

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.